• 1
    World Health Organization. Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other Influenza Viruses. Available at (Accessed 4 February 2013).
  • 2
    World Health Organization. Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics. Available at (Accessed 4 February 2013).
  • 3
    Centers for Disease Control and Prevention. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-10 season. Available at (Accessed 8 June 2013).
  • 4
    Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza.. Clinical aspects of pandemic influenza A (H1N1) virus infection. N Engl J Med 2009; 2010(362):170819.
  • 5
    Buda S, Kopke K, Haas W. Epidemiological characteristics of the influenza pandemic (H1N1) 2009 in Germany based on the mandatory notification of cases. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2010; 53:122330.
  • 6
    World Health Organization. Comparable analysis of national pandemic influenza preparedness plans. Available at (Accessed 4 February 2013).
  • 7
    Mounier-Jack S, Jas R, Coker R. Progress and shortcomings in European national strategic plans for pandemic influenza. Bull World Health Organ 2007; 85:9239.
  • 8
    World Health Organization. Pandemic influenza preparedness and response: a WHO guidance document. Available at (Accessed 4 February 2013).
  • 9
    Garg S, Chaves SS, Perez A, et al. Reduced influenza antiviral treatment among children and adults hospitalized with laboratory-confirmed influenza infection in the year after the 2009 pandemic. Clin Infect Dis 2012; 55:e1821.
  • 10
    Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361:193544.
  • 11
    Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302:18729.
  • 12
    Louie JK, Yang S, Acosta M, et al. Treatment With Neuraminidase Inhibitors for Critically Ill Patients With Influenza A (H1N1)pdm09. Clin Infect Dis 2012; 55:1198204.
  • 13
    Poeppl W, Hell M, Herkner H, et al. Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. Infection 2011; 39:34152.
  • 14
    Poggensee G, Gilsdorf A, Buda S, et al. The first wave of pandemic influenza (H1N1) 2009 in Germany: from initiation to acceleration. BMC Infect Dis 2010; 10:155.
  • 15
    Altmann M, Fiebig L, Soyka J, von Kries R, Dehnert M, Haas W. Severe cases of pandemic (H1N1) 2009 in children, Germany. Emerg Infect Dis 2011; 17:18692.
  • 16
    Altmann M, Fiebig L, Buda S, von Kries R, Dehnert M, Haas W. Unchanged Severity of Influenza A(H1N1)pdm09 Infection in Children during First Postpandemic Season. Emerg Infect Dis 2012; 18:175562.
  • 17
    Rodriguez A, Diaz E, Martin-Loeches I, et al. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother 2011; 66:11409.
  • 18
    Hernan MA, Lipsitch M. Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53:2779.
  • 19
    Wang K, Shun-Shin M, Gill P, Perera R, Harnden A. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev 2012; 4:CD002744.
  • 20
    Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:51224.
  • 21
    Deutsche Gesellschaft für pädiatrische Infektiologie e. V. Aktualisierte Empfehlung der DGPI zur Diagnostik, Therapie und Prophylaxe der Infektion mit dem Neuen Influenza A/H1N1v-Virus bei Kindern und Jugendlichen. Available at (Accessed 4 February 2013).
  • 22
    Schaberg T, Bauer T, Dalhoff K, et al. Management of a new influenza A/H1N1 virus pandemic within the hospital. Statement of the German Society of Pneumology. Pneumologie 2010; 64:1249.
  • 23
    Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR01):124.
  • 24
    Hoffken G, Lorenz J, Kern W, et al. Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia. Pneumologie 2010; 64:14954.
  • 25
    European Medicines Agency (EMEA). CHMP Assessment Report on Novel Influenza (H1N1) outbreak Tamiflu (oseltamivir) Relenza (zanamivir) EMEA/H/A-5.3/1172. Available at (Accessed 4 February 2013).
  • 26
    Siedler K, Skopnik H. Oseltamivir for treatment of influenza in infants less than one year: a retrospective analysis. Pediatr Infect Dis J 2010; 29:4958.
  • 27
    U.S. Food and Drug Administration. Label for Tamiflu, approved on 12/21/2012. Available at (Accessed 4 February 2013).
  • 28
    Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009; 339:b5106.
  • 29
    Jefferson T, Jones M, Doshi P, Del Mar C. Possible harms of oseltamivir - a call for urgent action. Lancet 2009; 374:13123.
  • 30
    National Association of Statutory Health Insurance Physicians. Oseltamivir (Tamiflu); Zanamivir (Relenza). Available at (Accessed 4 February 2013).
  • 31
    Borders-Hemphill V, Mosholder A. U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza Other Respi Viruses 2012; 6:e12933.
  • 32
    World Health Organization. Global monitoring of antiviral resistance in currently circulating human influenza viruses. Wkly Epidemiol Rec 2011; 86:497501.
  • 33
    Greene SK, Shay DK, Yin R, et al. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respi Viruses 2012; 6:e14351.
  • 34
    Blanchon T, Mentre F, Charlois-Ou C, et al. Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008-2009 winter. Clin Microbiol Infect 2013; 19:196203.
  • 35
    Klein SL. Sex differences in prophylaxis and therapeutic treatments for viral diseases. Handb Exp Pharmacol 2012; 214:499522.
  • 36
    Wilking H, Buda S, von der Lippe E, et al. Mortality of 2009 pandemic influenza A(H1N1) in Germany. Euro Surveill 2010; 15:16.